+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI



Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI



Journal of Thoracic Disease 9(3): 470-473




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060054023

Download citation: RISBibTeXText

PMID: 28449447

DOI: 10.21037/jtd.2017.03.26


Related references

Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report. Oncotargets and Therapy 12: 51-56, 2018

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. Lung Cancer 127: 96-102, 2019

Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation. Lung Cancer 113: 14-17, 2018

Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired Egfr T790M mutation after recovery from Ac0010-induced interstitial lung disease. OncoTargets and Therapy Volume 12: 5545-5549, 2019

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an EGFR Mutation With a History of Acquired Resistance to Osimertinib. Internal Medicine 2019, 2019

EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. Lung Cancer 126: 133-138, 2018

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. Bmc Cancer 18(1): 1241-1241, 2018

KRAS and EGFR amplifications mediate resistance to rociletinib and osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR. Molecular Cancer Therapeutics 2018, 2018

The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer. Oncotarget 7(32): 51311-51319, 2016

P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing Egfr Mutation. Journal of Thoracic Oncology 13(10): S806-S807, 2018

A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. Cancer ChemoTherapy and Pharmacology 82(6): 1031-1038, 2018

134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC). Journal of Thoracic Oncology 11(4 Suppl.): S153-S154, 2016

Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial. Cancer Science 109(6): 1930-1938, 2018

Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer. Expert Review of Clinical Pharmacology 10(1): 31-38, 2016

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations. Oncotarget 8(40): 68123-68130, 2017